MediBeacon will nab $22.4 million via a staged financing from Pansend, which is a subsidiary of diversified holding company HC2 Holdings. The cash will go to bring its first product to market--a real-time, noninvasive kidney monitor.
Digital health player DynoSense expects to use its new $9.4 million Series A financing to gain FDA clearance for its handheld scanner that grabs more than 33 health metrics, including commonly monitored vital signs, in under one minute. Dubbed the Dyno, the device captures the data and sends it to the cloud for analysis that is subsequently sent to healthcare providers.
A survey conducted by Abbott concludes that most adults do not recognize common concussion symptoms.
An international entrepreneurial trio has developed a hand-worn ring that detects syphilis, gonorrhea, chlamydia and trichomoniasis--wirelessly transmitting the results to a smartphone or tablet in under one minute. Known as Hoope, the device has a retractable needle and an anesthetic system based on electrical pulses; it is slated to debut on crowdfunding site Indiegogo in January.
Life sciences will be a keystone to the newly re-conceptualized Google. Under the umbrella of the parent company Alphabet, life sciences will be the first standalone company to stand shoulder-to-shoulder with the search-engine focused Google.
Kindara hopes to make conception a bit less fretful for women. It has raised $5.3 million in seed financing for a launch slated for the end of this year of its Wink wireless basal thermometer that connects to a corresponding fertility tracking app. The startup expects the device/app combo will be useful for women both as a tool to ease conception, as well as a means of avoiding it.
Sharpening its edge in diagnostics is core to the revenue growth strategy at Roche. The biopharma's deal activity in the last week is certainly a testament to that. It will acquire Kapa Biosystems, which provides enzyme optimization for next-gen sequencing and PCR.
Move over Theranos, here comes Genalyte. The former has made a big splash in the last year as it works to make diagnostics that are cheaper, require only a drop of blood and directly available to consumers--but the latter is almost ready to make its gambit to offer a device for rapid diagnostic testing in the physician office using a single blood drop.
Not to be outdone by other big-picture diagnostics players raising huge chunks of cash for consumer genomics--industry bellwether Illumina has weighed in with its own gambit. It's creating a joint venture dubbed Helix that's starting out with more than $100 million from investors including Warburg Pincus, the Mayo Clinic and Sutter Hill Ventures.
Amid growing evidence that mammography alone is not sufficient in screening women with dense breast tissue for breast cancer, a new Mayo Clinic study shows that adding an innovative molecular breast imaging solution to traditional mammography could be more accurate and cost-effective.